Skip to content
Sun Pharma logo

Sun Pharma

Sun Pharmaceutical Industries Ltd

SUNPHARMA NSE
₹1,884.90 −15.10 (−0.79%)
Market Cap
₹4,52,251 Cr
P/E
41.25
View as Markdown
MCP
Close 20 Nov 2026 ₹1,884.90 1Y +104.10 +5.85%
Start ₹1,780.80

Key Fundamentals

LargecapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
20.50%
Debt to Equity
0.04
EPS (TTM)
₹45.70
Book Value
₹372.10
Market Cap
₹4,52,251 Cr
P/E (TTM)
41.25
P/B
5.07
ROE
16.00%
Dividend Yield
0.84%
EBITDA
₹19,703 Cr
52W High
₹2,046.90
52W Low
₹1,583.70
Day Range
₹1,883.00 – ₹1,910.00
Volume
19,16,054

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

Sun Pharma peer comparison
Sun Pharma (this company)
1,884.9041.254,52,2515.070.85%16.00%20.50%61,63110,987
11,180.5088.262,96,80716.490.27%16.50%22.00%12,1913,363
4,689.5077.801,78,3749.710.82%27.40%15.20%17,4002,099
2,294.6092.521,23,98020.450.04%18.30%17.80%7,8231,332
1,200.0028.631,19,7004.300.08%21.20%21.10%30,3784,303
1,390.2041.441,16,0372.990.57%11.20%13.00%33,0972,760
1,415.0039.451,14,3123.230.92%11.60%15.50%28,1392,855
Median 7 companies1,884.9041.441,23,9805.070.57%16.50%17.80%28,1392,855

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

49 Average

Data confidence 100/100

Category scores

Quality
55
Average
Returns, margins, earnings quality 22% weight
Valuation
68
Strong
Cheap vs sector & own history 24% weight
Growth
30
Poor
Sales & profit trajectory 9% weight
Financial Health
82
Strong
Solvency, leverage, coverage 9% weight
Momentum
22
Poor
Trend strength, vol-adjusted 12% weight
Ownership
31
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 34.1%

Weaknesses

2
  • Promoter holding has decreased over last quarter: -1.80%
  • The company has delivered a poor sales growth of 11.8% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish1612
OscillatorsBullish063
Moving AveragesStrong Bullish109

Key readings

RSI (14)
61.35
Neutral
MACD (12,26,9)
24.95
Bullish
SMA (50)
1,818.22
Bullish
SMA (200)
1,823.19
Bullish

As of

Analyst Rating

Based on 32 analysts
BUY88%

28 of 32 analysts rate Buy, 1 Hold, 3 Sell.

As of

BUY
28
88%
HOLD
1
3%
SELL
3
9%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+7.45%
5Y+11.78%
3Y+10.03%
1Y+11.19%
TTM+12.13%

Net profit

Net profit growth by window
10Y+7.36%
5Y+38.33%
3Y+10.57%
1Y+4.96%
TTM+4.79%

Operating cash flow

Operating cash flow growth by window
10Y+6.39%
5Y+15.02%
3Y+35.80%
1Y−11.75%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−0.46 pp
5Y+2.94 pp
3Y+1.68 pp
1Y−0.52 pp
TTM−0.81 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹31,578 Cr
Mar 2018₹26,489 Cr
Mar 2019₹29,066 Cr
Mar 2020₹32,838 Cr
Mar 2021₹33,498 Cr
Mar 2022₹38,654 Cr
Mar 2023₹43,886 Cr
Mar 2024₹48,497 Cr
Mar 2025₹52,578 Cr
Mar 2026₹58,462 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹7,846 Cr
Mar 2018₹2,542 Cr
Mar 2019₹3,208 Cr
Mar 2020₹4,172 Cr
Mar 2021₹2,272 Cr
Mar 2022₹3,389 Cr
Mar 2023₹8,513 Cr
Mar 2024₹9,610 Cr
Mar 2025₹10,965 Cr
Mar 2026₹11,509 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹5,012 Cr +28.7% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 13 Nov 2026
AI opinion · based on fundamentals
Risk medium

Sun Pharmaceutical Industries Ltd trades at ₹1,880 as of 2026-11-13 with a market capitalization of ₹4,51,075 crore and a trailing PE of 41.14x. The company is virtually debt-free with a debt-to-equity ratio of 0.06, and has compounded profits at 17% over five years, though TTM profit growth has moderated to 7%.

Bull Case 7
  • The company is nearly debt-free with a debt-to-equity ratio of just 0.06, providing significant financial flexibility and resilience against interest rate cycles.
  • Five-year compounded profit growth of 17% demonstrates sustained earnings expansion over a meaningful period.
  • ROCE of 17.94% indicates efficient deployment of capital, comfortably above typical cost-of-capital benchmarks for large-cap pharma companies.
  • TTM sales growth of 12% shows continued top-line momentum, matching the five-year compounded sales growth rate of 12%.
  • Consistent ROE averaging 16% over the last three and five years reflects reliable shareholder value creation, with the 10-year average at 14%.
  • The company has maintained a healthy dividend payout ratio of 34.1%, balancing reinvestment with shareholder returns at a current yield of 0.85%.
  • The stock has compounded at an 18% CAGR over five years and 17% over three years, reflecting sustained investor confidence and business momentum.
Bear Case 8
  • A trailing PE of 41.14x is elevated relative to broader market averages, leaving limited room for earnings disappointment.
  • TTM profit growth has decelerated sharply to 7%, down from the five-year compounded rate of 17%, signalling potential earnings growth fatigue.
  • Promoter holding decreased by 1.80% in the last quarter, which can signal reduced insider confidence or dilution concerns.
  • Price-to-book of 5.05x implies a rich premium to book value, which may compress if growth slows further.
  • Ten-year compounded sales growth of only 7% suggests the underlying revenue trajectory has been modest over longer periods despite recent improvement.
  • The stock trades roughly 8% below its 52-week high of ₹2,046.90, indicating the recent trend has turned from peak optimism.
  • ROE of 13.79% on a trailing basis has dipped below the three-year and five-year averages of 16%, hinting at near-term return dilution.
  • One-year stock CAGR of 7% lags the three-year and five-year CAGRs of 17% and 18% respectively, suggesting decelerating price momentum.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

21h ago

TL;DR: Sun Pharma's recent newsflow is largely procedural and governance-oriented, with no material headwinds surfacing. The ₹7,816 crore NCD raise and ESOP 2026 approval suggest the company is actively preparing capital for future growth. The appointment of Deloitte as auditors for a five-year term signals continued emphasis on governance. With upcoming investor meetings in mid-November, watch for fresh strategic or earnings guidance that could set the near-term tone.

Positives 3
  • ESOP 2026 and borrowing limits approved Oct 31

    Seven special resolutions passed via postal ballot on October 31, 2026, including a new ESOP 2026 plan and enhanced borrowing limits, signaling growth investment intent.

  • ₹7,816 crore NCD allotment Oct 26

    Completed private placement of ₹7,816 crore in non-convertible debentures on October 26, 2026, strengthening the company's capital base for expansion.

  • Deloitte appointed as auditors Oct 30

    Board approved Deloitte Haskins & Sells LLP as statutory auditors for five years from FY27 AGM, replacing SRBC & CO LLP, reinforcing governance standards.

Neutral 2
  • Investor meetings Nov 17-18 Nov 5

    Sun Pharma will participate in analyst and institutional investor conferences in Mumbai on November 17-18, 2026.

  • Q2FY27 earnings call recording live Oct 30

    Audio recording of the Q2FY27 earnings call has been made available per SEBI regulations.

Quarterly Results

₹ Cr
SUNPHARMA quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
12,192
12,381
11,983
12,653
13,291
13,675
12,959
13,851
14,478
15,521
14,612
15,300
16,199
Expenses
9,013
8,904
8,948
9,045
9,352
9,666
9,243
9,550
9,951
10,572
10,658
10,882
11,455
Operating Profit
3,179
3,477
3,035
3,608
3,939
4,009
3,716
4,302
4,527
4,948
3,954
4,418
4,744
OPM %
26%
28%
25%
29%
30%
29%
29%
31%
31%
32%
27%
29%
29%
Other Income
294
180
504
533
354
149
613
464
470
579
458
520
517
Interest
49
35
74
62
69
52
49
75
100
78
86
100
75
Depreciation
633
622
650
655
626
631
664
701
730
732
775
739
758
Exceptional Items
—
—
—
—
—
—
−362
−818
—
−489
—
—
−1,269
PBT
2,791
3,000
2,816
3,424
3,598
3,476
3,254
3,173
4,168
4,227
3,551
4,099
3,159
Tax %
14%
14%
5%
16%
16%
16%
34%
27%
25%
20%
23%
29%
37%
Net Profit
2,385
2,561
2,659
2,861
3,037
2,913
2,154
2,293
3,125
3,381
2,710
2,901
1,995
EPS (₹)
9.90
10.52
11.06
11.82
12.67
12.10
8.96
9.50
13.00
14.04
11.31
12.06
8.29
YoY Sales growth
11
10
10
6
9
10
8
9
9
13
13
10
12

Profit & Loss

₹ Cr
SUNPHARMA profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
27,392
28,487
31,578
26,489
29,066
32,838
33,498
38,654
43,886
48,497
52,578
58,462
61,631
Expenses
19,498
20,313
21,476
20,858
22,689
25,855
25,028
28,397
32,235
35,479
37,464
41,961
43,567
Operating Profit
7,894
8,174
10,102
5,631
6,377
6,983
8,470
10,258
11,650
13,018
15,114
16,501
18,064
OPM %
29%
29%
32%
21%
22%
21%
25%
27%
27%
27%
29%
28%
29%
Other Income
283
−42
610
−135
−258
382
−3,449
−3,505
459
865
1,444
1,895
316
Interest
579
523
400
518
555
303
141
127
172
238
231
339
339
Depreciation
1,195
1,038
1,265
1,500
1,753
2,053
2,080
2,144
2,529
2,557
2,575
2,938
3,005
PBT
6,403
6,571
9,048
3,479
3,810
5,010
2,799
4,481
9,408
11,088
13,752
15,119
15,037
Tax %
14%
14%
13%
26%
16%
16%
18%
24%
9%
13%
20%
24%
—
Net Profit
5,476
5,658
7,846
2,542
3,208
4,172
2,272
3,389
8,513
9,610
10,965
11,509
10,987
EPS (₹)
21.92
18.89
29.03
8.73
11.11
15.69
12.10
13.64
35.32
39.91
45.55
47.84
45.70
Div. Payout %
14%
5%
12%
23%
25%
25%
62%
73%
33%
34%
35%
33%
—
Sales growth
70
4
11
−16
10
13
2
15
14
11
8
11
12

Balance Sheet

₹ Cr
SUNPHARMA balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
207
241
240
240
240
240
240
240
240
240
240
240
240
Reserves
25,431
32,742
36,400
38,074
41,169
45,025
46,223
47,771
55,755
63,427
71,978
83,330
89,040
Borrowings
8,996
8,497
9,832
10,385
10,514
8,315
3,869
1,290
6,886
3,274
2,362
4,627
3,241
Other Liabilities
14,089
13,948
14,624
15,598
12,666
14,615
17,291
20,474
17,831
18,387
17,328
20,210
22,317
Total Liabilities
48,723
55,428
61,095
64,297
64,590
68,194
67,622
69,776
80,712
85,328
91,908
1,08,407
1,14,838
Fixed Assets
12,682
15,872
17,675
18,853
21,837
22,847
21,553
22,665
24,065
23,248
22,586
32,822
35,110
CWIP
2,039
2,175
2,801
2,465
1,411
1,220
1,567
1,287
4,973
5,354
6,644
3,052
1,864
Investments
2,716
1,830
1,192
7,143
7,903
10,143
9,612
12,849
14,824
15,026
18,354
24,723
16,449
Other Assets
31,286
35,550
39,427
35,837
33,439
33,984
34,890
32,975
36,849
41,700
44,324
47,811
61,415
Total Assets
48,723
55,428
61,095
64,297
64,590
68,194
67,622
69,776
80,712
85,328
91,908
1,08,407
1,14,838

Cash Flow

₹ Cr
SUNPHARMA cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
5,616
6,686
7,082
3,907
2,196
6,555
6,170
8,985
4,959
12,135
14,072
12,419
Investing
−1,502
−3,949
−4,186
−3,104
−310
−2,225
407
−5,556
−7,220
−763
−5,183
−10,405
Financing
−1,187
−1,889
−2,285
−1,539
−2,731
−5,715
−5,980
−5,193
2,376
−6,710
−7,906
−2,513
Net Cash Flow
2,927
848
611
−736
−844
−1,386
596
−1,765
115
4,662
983
−498
Free Cash Flow
3,316
3,353
3,492
2,013
−966
5,105
5,097
7,550
2,895
9,964
12,005
8,906
CFO/EBITDA
93
106
90
83
48
113
85
78
56
105
96
89

Ratios

SUNPHARMA financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
68
87
83
108
112
105
99
99
95
85
91
97
Inventory Days
307
370
307
338
366
311
378
315
360
338
348
363
Days Payable
178
207
197
234
192
142
167
158
194
194
210
232
Cash Conversion Cycle
197
251
193
212
285
274
310
255
261
229
228
228
Working Capital Days
−7
37
−4
−31
31
51
51
47
40
55
65
54
ROCE %
23%
18%
20%
10%
10%
10%
13%
17%
16%
17%
20%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sun Pharma insights

71 extracted metrics across FY07–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 52.68%
  • DIIs 22.27%
  • FIIs 14.36%
  • Public 6.71%
  • Others 3.99%

0.01% of promoter holding pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Sun Pharma

What does Sun Pharmaceutical Industries Ltd do?
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs).
Where is Sun Pharmaceutical Industries Ltd (SUNPHARMA) listed?
Sun Pharmaceutical Industries Ltd trades as SUNPHARMA on the NSE and under code 524715 on the BSE.
Which sector does Sun Pharmaceutical Industries Ltd belong to?
Sun Pharmaceutical Industries Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd has a market capitalisation of ₹4,52,251 Cr as of 20 Nov 2026, which places it in the Largecap band.
What is the PE ratio of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd trades at a PE ratio of 41.25 as of 20 Nov 2026, on earnings per share of ₹45.7, against a book value of ₹372.1 per share.
What is the 52-week high and low of Sun Pharmaceutical Industries Ltd?
Over the last 52 weeks Sun Pharmaceutical Industries Ltd has traded between ₹1,583.7 and ₹2,046.9 as of 20 Nov 2026.
Does Sun Pharmaceutical Industries Ltd pay dividends?
Sun Pharmaceutical Industries Ltd has a dividend yield of 0.84%.
What is the Return on Equity (ROE) of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd reported a return on equity of 16.00%. Its debt-to-equity ratio is 0.04.

Company Information

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.

CEO Mr. Dilip Shantilal Shanghvi
Employees 43,000
Listed 8 Feb 1995
Face Value ₹1
Shares Outstanding 2,39,93,34,970

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SUNPHARMA.md for Sun Pharmaceutical Industries Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More